CAR-T cell therapy is a promising therapy option under investigation for the treatment of myeloma.. Different products are being studied, many with preliminary results showing high rates of response. Up until now there have been no approved CAR-T products for myeloma, however, CAR-T is now a reality after the US Food and Drug Administration (FDA) approved idecabtagene vicleucel (Abecma) as the first CAR-T cell therapy for treatment of relapsed/refractory myeloma. Continue reading →

The European Commission (EC) has granted conditional marketing authorization for selinexor, a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with dexamethasone for the treatment of myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. Continue reading →

Chimeric antigen receptor T cell (CAR T-cell) therapy is a form of immunotherapy that is currently being investigated in clinical trials for the treatment of myeloma. Immunotherapy works by using your immune system to fight cancer. In CAR-T-cell treatment, a type of immune cell, known as T cells, are genetically programmed with a chimeric antigen receptor (CAR) protein that enables them to recognise and destroy cancerous myeloma cells in your body. Continue reading →

The 7th World Congress on Controversies in Multiple Myeloma (COMy) will be held virtually on 7 – 9 May 2021. Leading doctors in myeloma and AL amyloidosis will discuss the latest advances in the field and improvements in patient care. Continue reading →

The U.S. Food and Drug Administration (FDA) has approved melphalan flufenamide (PEPAXTO^®), also known as melflufen, in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory myeloma, who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. Continue reading →

An international multidisciplinary consortium, guided by the European Organisation for Research and Treatment of Cancer (EORTC), has been convened to generate recommendations to standardize the use, analysis, and interpretation of PRO data in cancer clinical trials. Myeloma Patients Europe (MPE) is one of the partners in this project representing the Workgroup or European Cancer Patient Advocacy Networks (WECAN). Continue reading →

CARAMBA is a Horizon 2020 project investigating an innovative immunotherapy for the treatment of myeloma called Chimeric Antigen Receptor T-cell (CAR-T) therapy. CAR-T is a form of immunotherapy, which has demonstrated outstanding efficacy against various haematologic malignancies. Continue reading →

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the conditional approval for selinexor in combination with dexamethasone for the treatment of adult myeloma patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. Continue reading →

CAR-T-cell treatment is thought to be one of the most promising therapies in development for the treatment of myeloma. There are several ongoing clinical trials evaluating the safety and efficacy of CAR-T-cells, and  some of the studies with very encouraging results. Continue reading →

It is with great sadness that we share that our friend, colleague, and fellow patient advocate, Anna Rovira, passed away during the night of the 26 January 2021 after a short but very intense battle against cancer. Continue reading →